Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

BACKGROUND: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...

詳細記述

保存先:
書誌詳細
出版年:Prostate Int
主要な著者: Rauch, Simon, Fong, Dominic, Morra, Elisa, Maines, Francesca, Caffo, Orazio, Spizzo, Gilbert
フォーマット: Artigo
言語:Inglês
出版事項: Asian Pacific Prostate Society 2016
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916059/
https://ncbi.nlm.nih.gov/pubmed/27358844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2016.02.002
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料